Arginase 2 deficiency reduces hyperoxia-mediated retinal neurodegeneration through the regulation of polyamine metabolism

Cell Death and Disease

Volumn 5, Issue 2, 2014, Pages

  Narayanan, S P ^a   Xu, Z ^a   Putluri, N ^b   Sreekumar, A ^b   Lemtalsi, T ^a   Caldwell, R W ^a   Caldwell, R B ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

arginase; hyperoxia; neurodegeneration; polyamine; retinopathy of prematurity

Indexed keywords

ARGINASE; ARGINASE 2; N,N' BIS(2,3 BUTADIENYL)PUTRESCINE; OXIDOREDUCTASE; SPERMINE OXIDASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARGINASE 2 DEFICIENCY; ARTICLE; BIRTH; CONTROLLED STUDY; ENZYME DEFICIENCY; HYPEROXIA; MASS SPECTROMETRY; METABOLIC REGULATION; MOUSE; MOUSE MODEL; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OXYGEN-INDUCED RETINOPATHY; POLYAMINE METABOLISM; PRIORITY JOURNAL; RETROLENTAL FIBROPLASIA;

ANIMALS; ANIMALS, NEWBORN; APOPTOSIS; ARGINASE; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; HYPERARGININEMIA; HYPEROXIA; MICE; MICE, KNOCKOUT; NEUROPROTECTIVE AGENTS; OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; POLYAMINES; RETINAL DEGENERATION; RETINAL NEURONS; RETINOPATHY OF PREMATURITY; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 84896746538     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.23     Document Type: Article

References (60)

1. Felderhoff-Mueser U, Bittigau P, Sifringer M, Jarosz B, Korobowicz E, Mahler L et al. Oxygen causes cell death in the developing brain. Neurobiol Dis 2004; 17: 273-282.
2. Gerstner B, DeSilva TM, Genz K, Armstrong A, Brehmer F, Neve RL et al. Hyperoxia causes maturation-dependent cell death in the developing white matter. J Neurosci 2008; 28: 1236-1245.
3. Yis U, Kurul SH, Kumral A, Cilaker S, Tugyan K, Genc S et al. Hyperoxic exposure leads to cell death in the developing brain. Brain Dev 2008; 30: 556-562.
4. O'Connor AR, Stephenson T, Johnson A, Tobin MJ, Moseley MJ, Ratib S et al. Long-Term ophthalmic outcome of low birth weight children with and without retinopathy of prematurity. Pediatrics 2002; 109: 12-18.
5. Barnaby AM, Hansen RM, Moskowitz A, Fulton AB. Development of scotopic visual thresholds in retinopathy of prematurity. Invest Ophthalmol Vis Sci 2007; 48: 4854-4860.
6. Fulton AB, Hansen RM. Photoreceptor function in infants and children with a history of mild retinopathy of prematurity. J Opt Soc Am A Opt Image Sci Vis 1996; 13: 566-571.
7. Fulton AB, Hansen RM, Petersen RA, Vanderveen DK. The rod photoreceptors in retinopathy of prematurity: An electroretinographic study. Arch Ophthalmol 2001; 119 505.
8. Wu WC, Lin RI, Shih CP, Wang NK, Chen YP, Chao AN et al. Visual acuity, optical components, and macular abnormalities in patients with a history of retinopathy of prematurity. Ophthalmology 2012; 119: 1907-1916.
9. Dembinska O, Rojas LM, Varma DR, Chemtob S, Lachapelle P. Graded contribution of retinal maturation to the development of oxygen-induced retinopathy in rats. Invest Ophthalmol Vis Sci 2001; 42: 1111-1118.
10. Liu K, Akula JD, Hansen RM, Moskowitz A, Kleinman MS, Fulton AB. Development of the electroretinographic oscillatory potentials in normal and ROP rats. Invest Ophthalmol Vis Sci 2006; 47: 5447-5452.
11. Akula JD, Mocko JA, Benador IY, Hansen RM, Favazza TL, Vyhovsky TC et al. The neurovascular relation in oxygen-induced retinopathy. Mol Vis 2008; 14: 2499-2508.
12. Akula JD, Hansen RM, Tzekov R, Favazza TL, Vyhovsky TC, Benador IY et al. Visual cycle modulation in neurovascular retinopathy. Exp Eye Res 2010; 91: 153-161.
13. Sennlaub F, Courtois Y, Goureau O. Inducible nitric oxide synthase mediates retinal apoptosis in ischemic proliferative retinopathy. J Neurosci 2002; 22: 3987-3993.
14. Brafman A, Mett I, Shafir M, Gottlieb H, Damari G, Gozlan-Kelner S et al. Inhibition of oxygen-induced retinopathy in RTP801-deficient mice. Invest Ophthalmol Vis Sci 2004; 45 3805.
15. Downie LE, Pianta MJ, Vingrys AJ,Wilkinson-Berka JL, Fletcher EL. Neuronal and glial cell changes are determined by retinal vascularization in retinopathy of prematurity. J Comp Neurol 2007; 504: 404-417.
16. Fletcher EL, Downie LE, Hatzopoulos K, Vessey KA, Ward MM, Chow CL et al. The significance of neuronal and glial cell changes in the rat retina during oxygen-induced retinopathy. Doc Ophthalmol 2010; 120: 67-86.
17. Stevenson L, Matesanz N, Colhoun L, Edgar K, Devine A, Gardiner TA et al. Reduced nitro-oxidative stress and neural cell death suggests a protective role for microglial cells in TNFalpha-/-mice in ischemic retinopathy. Invest Ophthalmol Vis Sci 2010; 51: 3291-3299.
18. Narayanan SP, Suwanpradid J, Saul A, Xu Z, Still A, Caldwell RWet al. Arginase 2 deletion reduces neuro-glial injury and improves retinal function in a model of retinopathy of prematurity. PLoS One 2011; 6: E22460.
19. Dzietko M, Boos V, Sifringer M, Polley O, Gerstner B, Genz K et al. A critical role for Fas/ CD-95 dependent signaling pathways in the pathogenesis of hyperoxia-induced brain injury. Ann Neurol 2008; 64: 664-673.
20. Vottier G, Pham H, Pansiot J, Biran V, Gressens P, Charriaut-Marlangue C et al. Deleterious effect of hyperoxia at birth on white matter damage in the newborn rat. Dev Neurosci 2011; 33: 261-269.
21. Natoli R, Valter K, Chrysostomou V, Stone J, Provis J. Morphological, functional and gene expression analysis of the hyperoxic mouse retina. Exp Eye Res 2011; 92: 306-314.
22. Geller S, Krowka R, Valter K, Stone J. Toxicity of hyperoxia to the retina: Evidence from the mouse. Adv Exp Med Biol 2006; 572: 425-437.
23. Wellard J, Lee D, Valter K, Stone J. Photoreceptors in the rat retina are specifically vulnerable to both hypoxia and hyperoxia. Vis Neurosci 2005; 22: 501-507.
24. Dorfman AL, Chemtob S, Lachapelle P. Postnatal hyperoxia and the developing rat retina: Beyond the obvious vasculopathy. Doc Ophthalmol 2010; 120: 61-66.
25. Elms SC, Toque HA, Rojas M, Xu Z, Caldwell RW, Caldwell RB. The role of arginase I in diabetes-induced retinal vascular dysfunction in mouse and rat models of diabetes. Diabetologia 2013; 56: 654-662.
26. Romero MJ, Iddings JA, Platt DH, Ali MI, Cederbaum SD, Stepp DW et al. Diabetes-induced vascular dysfunction involves arginase I. Am J Physiol Heart Circ Physiol 2012; 302: H159-H166.
27. Chen B, Calvert AE, Cui H, Nelin LD. Hypoxia promotes human pulmonary artery smooth muscle cell proliferation through induction of arginase. Am J Physiol Lung Cell Mol Physiol 2009; 297: L1151-L1159.
28. Jin Y, Calvert TJ, Chen B, Chicoine LG, Joshi M, Bauer JA et al. Mice deficient in Mkp-1 develop more severe pulmonary hypertension and greater lung protein levels of arginase in response to chronic hypoxia. Am J Physiol Heart Circ Physiol 2010; 298: H1518-H1528.
29. Hein TW, Zhang C, Wang W, Chang CI, Thengchaisri N, Kuo L. Ischemia-reperfusion selectively impairs nitric oxide-mediated dilation in coronary arterioles: Counteracting role of arginase. FASEB J 2003; 17: 2328-2330.
30. Jeyabalan G, Klune JR, Nakao A, Martik N, Wu G, Tsung A et al. Arginase blockade protects against hepatic damage in warm ischemia-reperfusion. Nitric Oxide 2008; 19 35.
31. Morrison LD, Kish SJ. Brain polyamine levels are altered in Alzheimer's disease. Neurosci Lett 1995; 197: 5-8.
32. Gomes-Trolin C, Nygren I, Aquilonius SM, Askmark H. Increased red blood cell polyamines in ALS and Parkinson's disease. Exp Neurol 2002; 177: 515-520.
33. Zahedi K, Huttinger F, Morrison R, Murray-Stewart T, Casero RA, Strauss KI. Polyamine catabolism is enhanced after traumatic brain injury. J Neurotrauma 2010; 27: 515-525.
34. Wood PL, Khan MA, Kulow SR, Mahmood SA, Moskal Jr. Neurotoxicity of reactive aldehydes: The concept of 'aldehyde load' as demonstrated by neuroprotection with hydroxylamines. Brain Res 2006; 1095: 190-199.
35. Takano K, Ogura M, Nakamura Y, Yoneda Y. Neuronal and glial responses to polyamines in the ischemic brain. Curr Neurovasc Res 2005; 2: 213-223.
36. Ivanova S, Batliwalla F, Mocco J, Kiss S, Huang J, Mack W et al. Neuroprotection in cerebral ischemia by neutralization of 3-Aminopropanal. Proc Natl Acad Sci USA 2002; 99 5584.
37. Pernet V, Bourgeois P, Di Polo A. A role for polyamines in retinal ganglion cell excitotoxic death. J Neurochem 2007; 103: 1481-1490.
38. Seiler N. Oxidation of polyamines and brain injury. Neurochem Res 2000; 25: 471-490.
39. Kruman I, Bruce-Keller AJ, Bredesen D, Waeg G, Mattson MP. Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis. J Neurosci 1997; 17: 5089-5100.
40. Ivanova S, Botchkina GI, Al-Abed Y, Meistrell M III, Batliwalla F, Dubinsky JM et al. Cerebral ischemia enhances polyamine oxidation: Identification of enzymatically formed 3-Aminopropanal as an endogenous mediator of neuronal and glial cell death. J Exp Med 1998; 188: 327-340.
41. Ong WY, Lim HM, Lim TM, Lutz B. Kainate-induced neuronal injury leads to persistent phosphorylation of cAMP response element-binding protein in glial and endothelial cells in the hippocampus. Exp Brain Res 2000; 131: 178-186.
42. McCracken E, Valeriani V, Simpson C, Jover T, McCulloch J, Dewar D. The lipid peroxidation by-product 4-hydroxynonenal is toxic to axons and oligodendrocytes. J Cereb Blood Flow Metab 2000; 20: 1529-1536.
43. Morrow EM, Belliveau MJ, Cepko CL. Two phases of rod photoreceptor differentiation during rat retinal development. J Neurosci 1998; 18: 3738-3748.
44. Narayanan SP, Rojas M, Suwanpradid J, Toque HA, Caldwell RW, Caldwell RB. Arginase in retinopathy. Prog Retin Eye Res 2013; 36: 260-280.
45. Casero RA, Pegg AE. Polyamine catabolism and disease. Biochem J 2009; 421: 323-338.
46. Fulton AB, Hansen RM, Moskowitz A, Barnaby AM. Multifocal ERG in subjects with a history of retinopathy of prematurity. Doc Ophthalmol 2005; 111: 7-13.
47. Lachapelle P, Dembinska O, Rojas LM, Benoit J, Almazan G, Chemtob S. Persistent functional and structural retinal anomalies in newborn rats exposed to hyperoxia. Can J Physiol Pharmacol 1999; 77: 48-55.
48. Morris Jr. SM. Recent advances in arginine metabolism: Roles and regulation of the arginases. Br J Pharmacol 2009; 157: 922-930.
49. Felderhoff-Mueser U, Taylor DL, Greenwood K, Kozma M, Stibenz D, Joashi UC et al. Fas/CD95/APO-1 can function as a death receptor for neuronal cells in vitro and in vivo and is upregulated following cerebral hypoxic-ischemic injury to the developing rat brain. Brain Pathol 2000; 10: 17-29.
50. Graham EM, Sheldon RA, Flock DL, Ferriero DM, Martin LJ, O'Riordan DP et al. Neonatal mice lacking functional Fas death receptors are resistant to hypoxic-ischemic brain injury. Neurobiol Dis 2004; 17: 89-98.
51. Sifringer M, Bendix I, Borner C, Endesfelder S, von Haefen C, Kalb A et al. Prevention of neonatal oxygen-induced brain damage by reduction of intrinsic apoptosis. Cell Death Dis 2012; 3: E250.
52. Luo X, Budihardjo I, Zou H, Slaughter C, Bid Wang X. A Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998; 94: 481-490.
53. Clarke P, Beckham JD, Leser JS, Hoyt CC, Tyler KL. Fas-mediated apoptotic signaling in the mouse brain following reovirus infection. J Virol 2009; 83 6170.
54. Mudduluru M, Zubrow AB, Ashraf QM, Delivoria-Papadopoulos M, Mishra OP. Tyrosine phosphorylation of apoptotic proteins during hyperoxia in mitochondria of the cerebral cortex of newborn piglets. Neurochem Res 2010; 35: 1003-1009.
55. Pocernich CB, Butterfield DA. Acrolein inhibits NADH-linked mitochondrial enzyme activity: Implications for Alzheimer's disease. Neurotox Res 2003; 5: 515-520.
56. Yu Z, Li W, Hillman J, Brunk UT. Human neuroblastoma (SH-SY5Y) cells are highly sensitive to the lysosomotropic aldehyde 3-Aminopropanal. Brain Res 2004 163-169.
57. Yu Z, Li W, Brunk UT. 3-Aminopropanal is a lysosomotropic aldehyde that causes oxidative stress and apoptosis by rupturing lysosomes. Apmis 2003; 111 652.
58. Basu HS, Thompson TA, Church DR, Clower CC, Mehraein-Ghomi F, Amlong CA et al. A small molecule polyamine oxidase inhibitor blocks androgen-induced oxidative stress and delays prostate cancer progression in the transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2009; 69: 7689-7695.
59. Dogan A, Rao AM, Hatcher J, Rao VL, Baskaya MK, Dempsey RJ. Effects of MDL 72527, a specific inhibitor of polyamine oxidase, on brain edema, ischemic injury volume, and tissue polyamine levels in rats after temporary middle cerebral artery occlusion. J Neurochem 1999; 72: 765-770.
60. Shi O, Morris Jr. SM, Zoghbi H, Porter CW, O'Brien WE. Generation of a mouse model for arginase II deficiency by targeted disruption of the arginase II gene. Mol Cell Biol 2001; 21 813.